The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Precision Medicine and Drug Development

• Publication date

  2017-05-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/23808993.2017.1347481
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

  2017cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?

  2016cited by this paper
• Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

  2016cited by this paper
• Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.

  2016cited by this paper
• Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

  2016cited by this paper
• Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

  2016cited by this paper
• Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

  2016cited by this paper
• Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

  2016cited by this paper
• Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

  2015cited by this paper
• Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.

  2015cited by this paper
• Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

  2015cited by this paper
• Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

  2014cited by this paper
• Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

  2014cited by this paper
• A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

  2014cited by this paper
• Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

  2013cited by this paper
• External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

  2013cited by this paper
• Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

  2013cited by this paper
• Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

  2013cited by this paper
• c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.

  2013cited by this paper
• Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients

  2012cited by this paper
• Targeting MET in cancer: rationale and progress

  2012cited by this paper
• Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).

  2011cited by this paper
• Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

  2011cited by this paper
• A direct role for Met endocytosis in tumorigenesis

  2011cited by this paper
• Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.

  2011cited by this paper
• R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

  2010cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.

  2010cited by this paper
• Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors

  2010cited by this paper
• Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.

  2010cited by this paper
• Myeloid Zinc Finger 1 Induces Migration, Invasion, and In vivo Metastasis through Axl Gene Expression in Solid Cancer

  2010cited by this paper
• Cross‐talk between the VEGF‐A and HGF signalling pathways in endothelial cells

  2009cited by this paper
• Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival

  2009cited by this paper
• The role of fibroblast growth factors in tumor growth.

  2009cited by this paper
• TAM receptors and the regulation of erythropoiesis in mice

  2009cited by this paper
• Crypt stem cells as the cells-of-origin of intestinal cancer

  2009cited by this paper
• TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

  2008cited by this paper
• Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

  2008cited by this paper
• Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia.

  2008cited by this paper
• Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1

  2008cited by this paper
• Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

  2007cited by this paper
• c-Met is essential for wound healing in the skin

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

  2007cited by this paper
• Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases

  2006cited by this paper
• Tumor–stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c‐Met pathway

  2006cited by this paper
• Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells.

  2006cited by this paper
• Hepatocyte growth factor can substitute for M-CSF to support osteoclastogenesis.

  2006cited by this paper
• Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts.

  2005cited by this paper
• Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis.

  2005cited by this paper
• Met provides essential signals for liver regeneration.

  2004cited by this paper
• Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation

  2003cited by this paper
• Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene.

  2003cited by this paper
• Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

  2002cited by this paper
• Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis

  2002cited by this paper
• Down-regulation of MET, the receptor for hepatocyte growth factor

  2001cited by this paper
• Hepatocyte growth factor is secreted by osteoblasts and cooperatively permits the survival of haematopoietic progenitors

  2001cited by this paper
• Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF.

  2000cited by this paper
• Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

  2000cited by this paper
• The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells

  1999cited by this paper
• Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis

  1998cited by this paper
• Purification and Cloning of Hepatocyte Growth Factor Activator Inhibitor Type 2, a Kunitz-type Serine Protease Inhibitor*

  1997cited by this paper
• Hepatocyte Growth Factor Activator Inhibitor, a Novel Kunitz-type Serine Protease Inhibitor*

  1997cited by this paper
• Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud

  1995cited by this paper
• Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

  1995cited by this paper
• Cancer statistics

  1989cited by this paper

• Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

  2021cites this paper
• Long progression-free survival with cabozantinib in a heavily pretreated patient with metastatic renal cell carcinoma: a case report

  2021cites this paper
• Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study

  2021cites this paper
• Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma.

  2019cites this paper
• Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue.

  2019cites this paper
• Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

  2019cites this paper
• Toward a genome-based treatment landscape for renal cell carcinoma.

  2019cites this paper
• Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution

  2019cites this paper
• Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor

  2019cites this paper